- In May 2023, Sebela Pharmaceuticals announced positive Phase 3 study results for its investigational Copper 175 mm² IUD. This next-generation, low-dose, hormone-free copper IUD has achieved a 99% efficacy rate over three years, with a Pearl Index of 0.96. The study, conducted at 42 centers across the U.S., found that the IUD was well-tolerated, with a reported 98.8% placement success rate. Both clinicians and participants provided positive feedback regarding the IUD.
- In August 2022, Bayer AG received FDA approval for a supplemental new drug application (sNDA) for Mirena IUD, extending its period of use to up to eight years. This approval is intended to ensure that women have access to the contraceptive options needed at various stages of their reproductive life
- In January 2024, Medicines360, a global nonprofit in women's health, and DKT WomanCare, a global distributor of contraceptive products, partnered to expand access to AVIBELA. AVIBELA is a cost-effective, high-quality hormonal IUD with over 99% effectiveness. This collaboration aims to increase awareness, accessibility, and usage of this highly effective contraceptive option
- In June 2023, Pregna International Limited, a company specializing in women's reproductive health, received an initial private equity investment of USD 16 million (₹130 crore) from India Life Sciences Fund III (ILSF III), managed by the private equity firm InvAscent. This investment aims to fuel Pregna's growth and empower them to address the evolving needs of women globally
